STAAR Surgical revenue more than doubles to $93.5 million

• STAAR Surgical reported Q2 2026 net sales of $93.5 million, up 111% year over year, as China sales more than doubled.
• Net income reached $8.1 million versus a $16.8 million loss last year, while STAA was initially unchanged at $25.41 in after-hours trading.
• Management has focused its 2026 strategy on revenue growth, profit expansion and faster product innovation while addressing operational and geopolitical pressures.

STAAR Surgical (NASDAQ:STAA) reported second-quarter 2026 net sales of $93.5 million, up 111% year over year, while net income improved to $8.1 million from a $16.8 million loss a year earlier.

The $93.5 million revenue result exceeded the roughly $90.6 million analyst estimate, although GAAP earnings of $0.16 per diluted share were below pre-release estimates of about $0.21–$0.22.

“We remain focused on resolving the remaining system issues in the third quarter and are confident in the continued momentum of our business,” said STAAR Surgical then-Co-CEO, President and Chief Operating Officer Warren Foust.

China sales reached $52.3 million, APAC sales rose 189%, Americas sales increased 12%, gross margin reached 74.5%, and cash and available-for-sale investments totaled $181.5 million at quarter-end.

Following the announcement the STAAR Surgical share price was unchanged at $25.41 in early after-hours trading.

Earlier in 2026, STAAR reported first-quarter net sales of $93.5 million, restored China shipments as distributor inventory normalized, and said its Nidau facility was planned to supply all China-bound EVO lenses during 2026.

STAAR also terminated its proposed Alcon merger in January after failing to secure enough shareholder votes, preannounced Q2 sales above $90 million in July, and appointed Warren Foust as President and Chief Executive Officer on August 4.